Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for VTE prevention in medically ill patients post-discharge
NCT02111564Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 37
01
Overview
A Phase 3 trial of rivaroxaban in venous thromboembolism (VTE), sponsored by Janssen Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02111564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111564.